Literature DB >> 656269

Bumetanide and frusemide: a comparison of dose-response curves in healthy men.

L E Ramsay, G T McInnes, J Hettiarachchi, J Shelton, P Scott.   

Abstract

1 Log dose-responses for the loop diuretics bumetanide and frusemide in healthy subjects deviated significantly from parallelism as regards urine volume and sodium excretion. Ignoring the nonparallelism the best estimate of natriuretic potency (bumetanide: frusemide) was 46:1 in the bumetanide dose range 0.5-2 mg. 2 For a given natriuresis the urinary potassium excretion following bumetanide was significantly lower than that for frusemide within this dose range. 3 The data illustrate the limitations of studies comparing diuretics at a single dose level. Extrapolation of the observed log dose-response curves provides one possible explanation for the relative potency (bumetanide: frusemide) of 20:1 reported when the drugs are used at high dosage in patients with renal failure.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 656269      PMCID: PMC1429271          DOI: 10.1111/j.1365-2125.1978.tb01631.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  17 in total

1.  Oral bumetanide in chronic renal failure.

Authors:  M E Allison; M K Lindsay; A C Kennedy
Journal:  Postgrad Med J       Date:  1975       Impact factor: 2.401

2.  The problem of bioassay and comparative potency of diuretics. I. Parenteral and oral mercurial diuretics.

Authors:  R V FORD; C L SPURR; J H MOYER
Journal:  Antibiotic Med Clin Ther (New York)       Date:  1957-11

3.  Renal action, therapeutic use, and pharmacokinetics of the diuretic bumetanide.

Authors:  D L Davies; A F Lant; N R Millard; A J Smith; J W Ward; G M Wilson
Journal:  Clin Pharmacol Ther       Date:  1974-02       Impact factor: 6.875

4.  Bumetanide, a new potent diuretic. A clinical evaluation in congestive heart failure.

Authors:  K H Olesen; B Sigurd; E Steiness; A Leth
Journal:  Acta Med Scand       Date:  1973 Jan-Feb

5.  Comparative study of the effects of metolazone and other diuretics on potassium excretion.

Authors:  J B Puschett; A Rastegar
Journal:  Clin Pharmacol Ther       Date:  1974-04       Impact factor: 6.875

6.  Pharmacological properties of 3-n-butylamino-4-phenoxy-5-sulfamylbenzoic acid (Bumetanide), a new potent diuretic.

Authors:  E H Ostergaard; M P Magnussen; C K Nielsen; E Eilertsen; H H Frey
Journal:  Arzneimittelforschung       Date:  1972-01

7.  Relative potency of prorenoate and spironolactone in normal man.

Authors:  L Ramsay; I Harrison; J Shelton; M Tidd
Journal:  Clin Pharmacol Ther       Date:  1975-10       Impact factor: 6.875

8.  Bumetanide: potent new "loop" diuretic.

Authors:  M J Asbury; P B Gatenby; S O'Sullivan; E Bourke
Journal:  Br Med J       Date:  1972-01-22

9.  Diuretic action of bumetanide in advanced chronic renal insufficiency.

Authors:  K J Berg; A Tromsdal; T E Wideroe
Journal:  Eur J Clin Pharmacol       Date:  1976-02-06       Impact factor: 2.953

10.  Aminobenzoic acid diuretics. 2. 4-Substituted-3-amino-5-sulfamylbenzoic acid derivatives.

Authors:  P W Feit
Journal:  J Med Chem       Date:  1971-05       Impact factor: 7.446

View more
  14 in total

Review 1.  Clinical pharmacology of the loop diuretics furosemide and bumetanide in neonates and infants.

Authors:  Gian Maria Pacifici
Journal:  Paediatr Drugs       Date:  2012-08-01       Impact factor: 3.022

2.  A study of two diuretic/potassium combinations in heart failure.

Authors:  M Hussain; K Walton; C Davidson; D B Morgan
Journal:  Postgrad Med J       Date:  1985-01       Impact factor: 2.401

3.  Pharmacokinetics of intravenously administered bumetanide in man.

Authors:  P J Pentikäinen; P J Neuvonen; M Kekki; A Penttilä
Journal:  J Pharmacokinet Biopharm       Date:  1980-06

4.  A comparison of the pharmacokinetics and diuretic effects of two loop diuretics, torasemide and furosemide, in normal volunteers.

Authors:  L Dodion; Y Ambroes; N Lameire
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

5.  Pharmacokinetics and pharmacodynamics of ramipril and piretanide administered alone and in combination.

Authors:  G Ruf; S Gera; H G Luus; D Trenk; N de la Rey; K Löffler; W Schulz; E Jähnchen
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

6.  Immediate effects of bumetanide on systemic haemodynamics and left ventricular volume in acute and chronic heart failure.

Authors:  S P Verma; B Silke; G Reynolds; P Muller; M A Frais; S H Taylor
Journal:  Br J Clin Pharmacol       Date:  1987-07       Impact factor: 4.335

7.  Studies on the mechanism and characteristics of action of a uricosuric diuretic, indacrinone (MK-196).

Authors:  B A Brooks; E M Blair; R Finch; A F Lant
Journal:  Br J Clin Pharmacol       Date:  1980-09       Impact factor: 4.335

8.  Mineral excretion following furosemide compared with bumetanide therapy in premature infants.

Authors:  S Shankaran; K C Liang; N Ilagan; L Fleischmann
Journal:  Pediatr Nephrol       Date:  1995-04       Impact factor: 3.714

9.  Comparison of the chronic effects of bendrofluazide, bumetanide and frusemide on plasma biochemical variables.

Authors:  R Gabriel; P Baylor
Journal:  Postgrad Med J       Date:  1981-02       Impact factor: 2.401

Review 10.  Bumetanide. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use.

Authors:  A Ward; R C Heel
Journal:  Drugs       Date:  1984-11       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.